# Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

> **NCT04806035** · PHASE1 · TERMINATED · sponsor: **TG Therapeutics, Inc.** · enrollment: 21 (actual)

## Conditions studied

- CLL
- SLL
- Richter's Transformation
- Indolent Lymphoma
- Follicular Lymphoma
- Marginal Zone Lymphoma
- Aggressive Lymphoma
- DLBCL
- Mediastinal Large B-cell Lymphoma
- MCL

## Interventions

- **BIOLOGICAL:** TG-1801
- **BIOLOGICAL:** Ublituximab

## Key facts

- **NCT ID:** NCT04806035
- **Lead sponsor:** TG Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-28
- **Primary completion:** 2024-06-12
- **Final completion:** 2024-06-12
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Strategic/Business Decision
- **Last updated:** 2024-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04806035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04806035, "Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04806035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*